Insmed reported $16.15B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
BioMarin Pharmaceutical USD 10.95B 667M Nov/2026
Cytokinetics USD 7.51B 1.66B Nov/2026
DBV Technologies USD 739M 491M Sep/2026
Gilead Sciences USD 184.82B 27.96B Sep/2026
Heron Therapeutics USD 238M 7M Dec/2025
Insmed USD 24.93B 1.82B Sep/2026
Novartis USD 328.21B 54.92B Nov/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
Ultragenyx Pharmaceutical USD 1.37B 108M Nov/2026
Vertex Pharmaceuticals USD 142.88B 10.37B Nov/2026